UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

The New England journal of medicine, 2021-08, Vol.385 (6), p.503-515

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-03, Vol.315 (9), p.898

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Diabetes care, 2014-08, Vol.37 (8), p.2168-2176

2014

Link zum Volltext

Verfügbarkeit prüfen

Ultra‐rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double‐blind phase 3 study

Diabetes, obesity & metabolism, 2024-01, Vol.26 (1), p.311-318

2024

Link zum Volltext

Verfügbarkeit prüfen

84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

The Lancet (British edition), 2021-11, Vol.398 (10313), p.1811-1824

2021

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia in patients with type 1 and type 2 diabetes mellitus on insulin therapy. Results of the global HAT study in Argentina

Medicina (Buenos Aires), 2017, Vol.77 (6), p.449-457

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program

Endocrine practice, 2016-12, Vol.22 (12), p.1406-1414

2016

Link zum Volltext

Verfügbarkeit prüfen

Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S48

2018

Link zum Volltext

Verfügbarkeit prüfen

140 - Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S48-S48

2018

Link zum Volltext

Verfügbarkeit prüfen

CA-190 - Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A113-A114

2017

Link zum Volltext

Verfügbarkeit prüfen

Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100)

Diabetes & metabolism, 2017-03, Vol.43 (2), p.A113-A114

2017

Link zum Volltext

Verfügbarkeit prüfen

23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR)

Nederlands Tijdschrift voor Diabetolog, 2015-09, Vol.13 (3), p.78-79

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(14)

Sprache

Erscheinungsjahr

n.n

Thema

Diabetes
(8)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Humans
(7)
Diabetes Mellitus, Type 2 - Drug Therapy
(5)
Female
(5)
Glucose
(5)
Hemoglobin
(5)
Male
(5)
Middle Aged
(5)
Antidiabetics
(4)
Diabetes Mellitus
(4)
Drug Therapy
(4)
General & Internal Medicine
(4)
Glycated Hemoglobin A - Analysis
(4)
Hypoglycemia
(4)
Hypoglycemic Agents - Administration & Dosage
(4)
Hypoglycemic Agents - Adverse Effects
(4)
Medicine, General & Internal
(4)
Adult
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Ultra‐rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double‐blind phase 3 study

84-LB: Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Hypoglycaemia in patients with type 1 and type 2 diabetes mellitus on insulin therapy. Results of the global HAT study in Argentina

Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program

Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine

140 - Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine

CA-190 - Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100)

Les diabétiques de type 2 traités par insuline degludec/liraglitude (IDegLira) ont plus de chances d’atteindre les objectifs glycémiques sans hypoglycémies ni prise de poids qu’avec l’insuline Glargine U100 (IGlar U100)

23. Insulin Degludec/Liraglutide (IDegLira) Is Superior to Insulin Glargine (IG) in A1c Reduction, Risk of Hypoglycemia, and Weight Change: DUAL V Study (166-OR)

Suchergebnisse filtern